The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yung-Jue Bang
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; BeiGene; Green Cross; Hanmi; Merck Serono; MSD Oncology; Novartis; Samyang; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hyun Cheol Chung
Consulting or Advisory Role - Bristol-Myers Squibb; Celltrion; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
 
Hiroshi Yabusaki
No Relationships to Disclose
 
Satoru Iwasa
Honoraria - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Otsuka (Inst)
 
Daisuke Sakai
Speakers' Bureau - Chugai Pharma
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Kei Muro
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst)
 
Naotoshi Sugimoto
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hisateru Yasui
Honoraria - Becton Dickinson; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Medicon; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; TERUMO; Yakult Honsha
 
Makio Gamoh
Honoraria - Chugai Pharma; Daiichi Sankyo; Lilly; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Yasuko Murakawa
No Relationships to Disclose
 
Yuji Negoro
No Relationships to Disclose
 
Tomohiro Nishina
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hisashi Hosaka
No Relationships to Disclose
 
Yasushi Omuro
Research Funding - Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Yoshinori Kawaguchi
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Masahiro Sugihara
Employment - Daiichi Sankyo
 
Kaku Saito
Employment - Daiichi Sankyo
 
Rita Dalal
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo; Lilly
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)